Sino Biopharmaceutical Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $1.00
50-Day Range
MA: $1.05
52-Week Range
Now: $1.00
Average Volume5,383 shs
Market Capitalization$18.88 billion
P/E RatioN/A
Dividend YieldN/A
Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical logo

Industry, Sector and Symbol

Industry Private households
Previous SymbolNASDAQ:SBMFF
Year FoundedN/A



Sales & Book Value

Annual Sales$3.51 billion
Cash Flow$0.05 per share
Book Value$0.31 per share



Outstanding Shares18,882,450,000
Market Cap$18.88 billion
Next Earnings DateN/A
OptionableNot Optionable


Sino Biopharmaceutical Ltd.
December 18, 2020 |  wsj.com
Sino Biopharmaceutical Ltd (SBMFF)
August 2, 2020 |  www.nasdaq.com
Sino Biopharmaceutical Limited (SBMFF)
December 12, 2019 |  finance.yahoo.com
China pharma: the promised land
November 28, 2019 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.80 out of 5 stars

Medical Sector

1193rd out of 2,025 stocks

Private Households Industry

203rd out of 378 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBMFF News and Ratings via Email

Sign-up to receive the latest news and ratings for SBMFF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sino Biopharmaceutical (OTCMKTS:SBMFF) Frequently Asked Questions

Is Sino Biopharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sino Biopharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Sino Biopharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBMFF, but not buy additional shares or sell existing shares.
View analyst ratings for Sino Biopharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Sino Biopharmaceutical?

Wall Street analysts have given Sino Biopharmaceutical a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sino Biopharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sino Biopharmaceutical?

Sino Biopharmaceutical saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,084,900 shares, a decrease of 93.7% from the March 15th total of 17,323,200 shares. Based on an average daily volume of 10,600 shares, the short-interest ratio is presently 102.3 days.
View Sino Biopharmaceutical's Short Interest

How has Sino Biopharmaceutical's stock been impacted by Coronavirus?

Sino Biopharmaceutical's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SBMFF shares have decreased by 30.6% and is now trading at $1.00.
View which stocks have been most impacted by COVID-19

Who are Sino Biopharmaceutical's key executives?

Sino Biopharmaceutical's management team includes the following people:
  • Ms. Y. Y. Tse, Exec. Chairman (Age 29, Pay $3.76M)
  • Mr. Ping Tse, Founder & Sr. Vice Chairman (Age 69, Pay $6.8M)
  • Ms. Cheung Ling Cheng, Exec. Vice Chairwoman of the Board (Age 57, Pay $4.26M)
  • Ms. Mingqin Li, VP & Exec. Director (Age 62, Pay $150.13k)
  • Mr. Zhoushan Tian, Exec. Director (Age 57, Pay $370.82k)
  • Mr. Hsin Tse, VP & Exec. Director (Age 51, Pay $483.45k)
  • Mr. Eric S. Y. Tse, Exec. Director (Age 25, Pay $939.32k)
  • Mr. Yi Li, CEO & Exec. Director (Age 59)
  • Ms. Jiayin Jennie Ma, Group Chief Financial Officer (Age 45)
  • Ms. Fai Chia, VP & Assistant to the Founding Chairman (Age 63)

Who are some of Sino Biopharmaceutical's key competitors?

What is Sino Biopharmaceutical's stock symbol?

Sino Biopharmaceutical trades on the OTCMKTS under the ticker symbol "SBMFF."

How do I buy shares of Sino Biopharmaceutical?

Shares of SBMFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sino Biopharmaceutical's stock price today?

One share of SBMFF stock can currently be purchased for approximately $1.00.

How much money does Sino Biopharmaceutical make?

Sino Biopharmaceutical has a market capitalization of $18.88 billion and generates $3.51 billion in revenue each year.

How many employees does Sino Biopharmaceutical have?

Sino Biopharmaceutical employs 24,108 workers across the globe.

What is Sino Biopharmaceutical's official website?

The official website for Sino Biopharmaceutical is www.sinobiopharm.com.

Where are Sino Biopharmaceutical's headquarters?

Sino Biopharmaceutical is headquartered at Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, .

How can I contact Sino Biopharmaceutical?

Sino Biopharmaceutical's mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company can be reached via phone at 852-2802-9886 or via email at [email protected]

This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.